Kit Identifies Endonuclease Impurities for Gene Therapy

May 1, 2019

Source: Pharmaceutical Technology's In the Lab eNewsletter

Issue 5,Volume 14

Cygnus Technologies has developed the EndonucleaseGTP ELISA Kit to quantitate and detect residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.

The EndonucleaseGTP ELISA Kit from Cygnus Technologies detects and quantitates residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy. With a detection limit of ~0.06 ng/mL, the kit is three times more sensitive than the only other commercially available assay for detection and quantitation of these endonuclease impurities, according to the company. The kit also contains all the necessary, ready-to-use reagents for 96 analyses in microplate format, including a set of calibrated endonuclease standards. The assay can be easily integrated into desired workflow points-from process development to quality control to lot release testing.

Cygnus Technologies